Therriault, Joseph http://orcid.org/0000-0002-7826-4781
Schindler, Suzanne E. http://orcid.org/0000-0002-1680-1465
Salvadó, Gemma http://orcid.org/0000-0002-5210-9230
Pascoal, Tharick A.
Benedet, Andréa Lessa
Ashton, Nicholas J.
Karikari, Thomas K. http://orcid.org/0000-0003-1422-4358
Apostolova, Liana
Murray, Melissa E. http://orcid.org/0000-0001-7379-2545
Verberk, Inge http://orcid.org/0000-0003-0341-7445
Vogel, Jacob W.
La Joie, Renaud http://orcid.org/0000-0003-2581-8100
Gauthier, Serge
Teunissen, Charlotte
Rabinovici, Gil D.
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Bateman, Randall J. http://orcid.org/0000-0002-7729-1702
Scheltens, Philip
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Sperling, Reisa
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Jack, Clifford R. Jr http://orcid.org/0000-0001-7916-622X
Rosa-Neto, Pedro http://orcid.org/0000-0001-9116-1376
Article History
Accepted: 5 February 2024
First Online: 1 March 2024
Competing interests
: J.T. has received consultancy fees from the Neurotorium educational platform outside the scope of the present work. L.A. has received grants from the National Institute on Aging, the Alzheimer’s Association, AVID Radiopharmaceuticals, Life Molecular Imaging, and Roche Diagnostics and personal fees from Eli Lilly, Biogen, Two Labs, IQVIA, Genentech, Siemens, Corium, GE Healthcare, Eisai, Roche Diagnostics, Alnylam, the Alzheimer’s Association, and from the FDA outside the submitted work. C.T. reports non-financial support from Quanterix during the conduct of the study, has a patent pending for glial fibrillary acidic protein as a biomarker, serves as an editorial board member of <i>Alzheimer’s Research and Therapy</i>, <i>Medidact Neurologie</i> (Springer), and <i>Neurology: Neuroimmunology & Neuroinflammation</i>, serves as an editor of the Neuromethods book series (Springer), and reports grants from Roche Diagnostics, non-financial support from ADx Neurosciences and Eli Lilly, and compensation from AC Immune, Axon Neurosciences, Biogen, Brainstorm Cell Therapeutics, Celgene, Denali Therapeutics, EIP Pharma, Eisai, PeopleBio, Toyama Pharmaceutical Association and Vivoryon Therapeutics outside the submitted work. G.D.R. has received grants from the American College of Radiology, Avid Radiopharmaceuticals, Life Molecular Imaging (formerly Piramal Imaging) and GE Healthcare during the conduct of the study, personal fees from Alector, Eli Lilly, Merck, and the Johnson & Johnson Data and Safety Monitoring Board and grants from Genentech, the NIH, the Alzheimer’s Association, and Rainwater Charitable Foundation outside the submitted work, and is an Associate Editor for <i>JAMA Neurology</i>. R.J.B. declares research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb and Novartis, equity ownership interest in C2N Diagnostics and income from C2N Diagnostics for serving on the scientific advisory board, serves on the Roche gantenerumab steering committee as an unpaid member, has income based on technology (blood plasma assay and methods of diagnosing Alzheimer disease with phosphorylation changes) licensed by Washington University to C2N Diagnostics, and also declares involvement with the Alzheimer’s Association, Duke Margolis Alzheimer’s, BrightFocus Foundation and Tau Consortium Investigators’ Meeting. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work). P.S. is a full-time employee of EQT Life Sciences (formerly LSP) and Professor Emeritus at Amsterdam University Medical Centers. He has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell and Green Valley. Within his university affiliation, he was the global Principal Investigator of a phase Ib study for AC Immune, a phase IIb study for FUJI-film/Toyama and a phase II study for UCB. He is past chair of the European Union steering committee of the Vivoryon phase IIb programme and a phase IIb study for Novartis Cardiology, and is currently co-chair of a phase III study for Novo Nordisk. K.B. has served as a consultant and on advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics and Siemens Healthineers, has served on data monitoring committees for Julius Clinical and Novartis, has given lectures, produced educational materials and participated in educational programmes for Biogen, Eisai and Roche Diagnostics, and is a co-founder of BBS, which is part of the GU Ventures Incubator Program, outside the work presented in this paper. R.S. reports grant support from the NIH, Eli Lilly, the Alzheimer’s Association, GHR Foundation, Fidelity, and Gates Ventures, non-financial support from CogState and Mount Sinai, grants and personal fees from Janssen, and personal fees from AC Immune, Biogen, Neurocentria, Eisai, Roche, Takeda and Novartis. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy or speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. P.R.-N. has served on scientific advisory boards and/or as a consultant for Roche, Novo Nordisk, Eisai and Cerveau Technologies. The other authors declare no competing interests.